{
    "clinical_study": {
        "@rank": "23300", 
        "arm_group": {
            "arm_group_label": "LEO 90105 Ointment", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The pharmacokinetics of LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate) in\n      Japanese subjects with extensive psoriasis vulgaris."
        }, 
        "brief_title": "The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                        "title": "LEO 90105 Ointment"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "13"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "0"
                                            }
                                        }, 
                                        "sub_title": "<=18 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "8"
                                            }
                                        }, 
                                        "sub_title": "Between 18 and 65 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "5"
                                            }
                                        }, 
                                        "sub_title": ">=65 years"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Age", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "15.4", 
                                            "@value": "54.2"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "3"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "10"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "13"
                                        }
                                    }, 
                                    "sub_title": "Japan"
                                }
                            }, 
                            "param": "Number", 
                            "title": "Region of Enrollment", 
                            "units": "participants"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "LEO acknowledges the investigators right to publish the entire results of the study, irrespective of outcome. LEO retains the right to have any publication submitted to LEO for review. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO."
            }, 
            "limitations_and_caveats": "None", 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "The mean Cmax(Maximum Observed Plasma Concentration) of betamethasone dipropionate was determined.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "#text": "The pharmacokinetic parameter could not be reliably estimated", 
                                                    "@group_id": "O1", 
                                                    "@spread": "NA", 
                                                    "@value": "NA"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The mean Cmax(Maximum Observed Plasma Concentration) of betamethasone dipropionate was determined.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: Cmax of Betamethasone Dipropionate", 
                                    "units": "pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 1", 
                        "title": "Pharmacokinetic: Cmax of Betamethasone Dipropionate", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone dipropionate was determined", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "#text": "The  pharmacokinetic parameter could not be reliably estimated", 
                                                    "@group_id": "O1", 
                                                    "@spread": "NA", 
                                                    "@value": "NA"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone dipropionate was determined", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: Cmax of Betamethasone Dipropionate", 
                                    "units": "pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 7", 
                        "title": "Pharmacokinetic: Cmax of Betamethasone Dipropionate", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone dipropionate was determined", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "#text": "The  pharmacokinetic parameter could not be reliably estimated", 
                                                    "@group_id": "O1", 
                                                    "@spread": "NA", 
                                                    "@value": "NA"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone dipropionate was determined", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: Cmax of Betamethasone Dipropionate", 
                                    "units": "pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 14", 
                        "title": "Pharmacokinetic: Cmax of Betamethasone Dipropionate", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone dipropionate was determined", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "#text": "The  pharmacokinetic parameter could not be reliably estimated", 
                                                    "@group_id": "O1", 
                                                    "@spread": "NA", 
                                                    "@value": "NA"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone dipropionate was determined", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: AUClast of Betamethasone Dipropionate", 
                                    "units": "h*pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 1", 
                        "title": "Pharmacokinetic: AUClast of Betamethasone Dipropionate", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone dipropionate was determined", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "#text": "The  pharmacokinetic parameter could not be reliably estimated", 
                                                    "@group_id": "O1", 
                                                    "@spread": "NA", 
                                                    "@value": "NA"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone dipropionate was determined", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: AUClast of Betamethasone Dipropionate", 
                                    "units": "h*pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 7", 
                        "title": "Pharmacokinetic: AUClast of Betamethasone Dipropionate", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone dipropionate was determined", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "#text": "The  pharmacokinetic parameter could not be reliably estimated", 
                                                    "@group_id": "O1", 
                                                    "@spread": "NA", 
                                                    "@value": "NA"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone dipropionate was determined", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: AUClast of Betamethasone Dipropionate", 
                                    "units": "h*pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 14", 
                        "title": "Pharmacokinetic: AUClast of Betamethasone Dipropionate", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The mean Cmax(Maximum Observed Plasma Concentration) of betamethasone 17- propionate was determined", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "351.01", 
                                                    "@value": "218.8"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The mean Cmax(Maximum Observed Plasma Concentration) of betamethasone 17- propionate was determined", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: Cmax of Betamethasone 17-propionate", 
                                    "units": "pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 1", 
                        "title": "Pharmacokinetic: Cmax of Betamethasone 17-propionate", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone 17- propionate was determined", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "77.551", 
                                                    "@value": "101.5"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone 17- propionate was determined", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: Cmax of Betamethasone 17-propionate", 
                                    "units": "pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 7", 
                        "title": "Pharmacokinetic: Cmax of Betamethasone 17-propionate", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone 17- propionate was determined", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "64.826", 
                                                    "@value": "116"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone 17- propionate was determined", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: Cmax of Betamethasone 17-propionate", 
                                    "units": "pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 14", 
                        "title": "Pharmacokinetic: Cmax of Betamethasone 17-propionate", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone 17-propionate was determined", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "1885.01", 
                                                    "@value": "1036.7"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone 17-propionate was determined", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: AUClast of Betamethasone 17-propionate", 
                                    "units": "h*pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 1", 
                        "title": "Pharmacokinetic: AUClast of Betamethasone 17-propionate", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone 17-propionate was determined", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "517.107", 
                                                    "@value": "570.92"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone 17-propionate was determined", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: AUClast of Betamethasone 17-propionate", 
                                    "units": "h*pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 7", 
                        "title": "Pharmacokinetic: AUClast of Betamethasone 17-propionate", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone 17-propionate was determined", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "467.426", 
                                                    "@value": "634.65"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone 17-propionate was determined", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: AUClast of Betamethasone 17-propionate", 
                                    "units": "h*pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 14", 
                        "title": "Pharmacokinetic: AUClast of Betamethasone 17-propionate", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The mean Cmax (Maximum Observed Plasma Concentration) of calcipotriol was determined", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "#text": "The  pharmacokinetic parameter could not be reliably estimated", 
                                                    "@group_id": "O1", 
                                                    "@spread": "NA", 
                                                    "@value": "107.6"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The mean Cmax (Maximum Observed Plasma Concentration) of calcipotriol was determined", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: Cmax of Calcipotriol", 
                                    "units": "pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 1", 
                        "title": "Pharmacokinetic: Cmax of Calcipotriol", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The mean Cmax (Maximum Observed Plasma Concentration) of calcipotriol was determined", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "#text": "The  pharmacokinetic parameter could not be reliably estimated", 
                                                    "@group_id": "O1", 
                                                    "@spread": "NA", 
                                                    "@value": "NA"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The mean Cmax (Maximum Observed Plasma Concentration) of calcipotriol was determined", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: Cmax of Calcipotriol", 
                                    "units": "pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 7", 
                        "title": "Pharmacokinetic: Cmax of Calcipotriol", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The mean Cmax (Maximum Observed Plasma Concentration) of calcipotriol was determined", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "#text": "The  pharmacokinetic parameter could not be reliably estimated", 
                                                    "@group_id": "O1", 
                                                    "@spread": "NA", 
                                                    "@value": "NA"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The mean Cmax (Maximum Observed Plasma Concentration) of calcipotriol was determined", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: Cmax of Calcipotriol", 
                                    "units": "pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 14", 
                        "title": "Pharmacokinetic: Cmax of Calcipotriol", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for calcipotriol was determined", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "#text": "The  pharmacokinetic parameter could not be reliably estimated", 
                                                    "@group_id": "O1", 
                                                    "@spread": "NA", 
                                                    "@value": "169.6"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for calcipotriol was determined", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: AUClast of Calcipotriol", 
                                    "units": "h*pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 1", 
                        "title": "Pharmacokinetic: AUClast of Calcipotriol", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for calcipotriol was determined", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "#text": "The  pharmacokinetic parameter could not be reliably estimated", 
                                                    "@group_id": "O1", 
                                                    "@spread": "NA", 
                                                    "@value": "NA"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for calcipotriol was determined", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: AUClast of Calcipotriol", 
                                    "units": "h*pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 7", 
                        "title": "Pharmacokinetic: AUClast of Calcipotriol", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for calcipotriol was determined", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "#text": "The  pharmacokinetic parameter could not be reliably estimated", 
                                                    "@group_id": "O1", 
                                                    "@spread": "NA", 
                                                    "@value": "NA"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for calcipotriol was determined", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: AUClast of Calcipotriol", 
                                    "units": "h*pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 14", 
                        "title": "Pharmacokinetic: AUClast of Calcipotriol", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The mean Cmax (Maximum Observed Plasma Concentration) of MC1080 was determined", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "#text": "The  pharmacokinetic parameter could not be reliably estimated", 
                                                    "@group_id": "O1", 
                                                    "@spread": "NA", 
                                                    "@value": "95.35"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The mean Cmax (Maximum Observed Plasma Concentration) of MC1080 was determined", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: Cmax of MC1080", 
                                    "units": "pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 1", 
                        "title": "Pharmacokinetic: Cmax of MC1080", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The mean Cmax (Maximum Observed Plasma Concentration) of MC1080 was determined", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "36.218", 
                                                    "@value": "57.57"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The mean Cmax (Maximum Observed Plasma Concentration) of MC1080 was determined", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: Cmax of MC1080", 
                                    "units": "pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 7", 
                        "title": "Pharmacokinetic: Cmax of MC1080", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The mean Cmax (Maximum Observed Plasma Concentration) of MC1080 was determined", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "#text": "The  pharmacokinetic parameter could not be reliably estimated", 
                                                    "@group_id": "O1", 
                                                    "@spread": "NA", 
                                                    "@value": "NA"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The mean Cmax (Maximum Observed Plasma Concentration) of MC1080 was determined", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: Cmax of MC1080", 
                                    "units": "pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 14", 
                        "title": "Pharmacokinetic: Cmax of MC1080", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for MC 1080 was determined", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "#text": "The  pharmacokinetic parameter could not be reliably estimated", 
                                                    "@group_id": "O1", 
                                                    "@spread": "NA", 
                                                    "@value": "430.9"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for MC 1080 was determined", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: AUClast of MC1080", 
                                    "units": "h*pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 1", 
                        "title": "Pharmacokinetic: AUClast of MC1080", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "To assess the The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for MC 1080 was determined", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "175.16", 
                                                    "@value": "221.2"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "To assess the The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for MC 1080 was determined", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: AUClast of MC1080.", 
                                    "units": "h*pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 7", 
                        "title": "Pharmacokinetic: AUClast of MC1080.", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for MC 1080 was determined", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "#text": "The  pharmacokinetic parameter could not be reliably estimated", 
                                                    "@group_id": "O1", 
                                                    "@spread": "NA", 
                                                    "@value": "NA"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for MC 1080 was determined", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Pharmacokinetic: AUClast of MC1080.", 
                                    "units": "h*pg/mL"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 14", 
                        "title": "Pharmacokinetic: AUClast of MC1080.", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Psoriasis Area and Severity Index (PASI) is based on the investigator's assessment of the disease.\nThe extent and severity of redness, thickness and scaliness of psoriasis are recorded for three regions (arms, trunk and legs) and these are used to calculate PASI. The PASI can range between 0 (best) to 64.8 (worst). m-PASI indicate that the scale is modified.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "24.5", 
                                                    "@value": "-72.4"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Psoriasis Area and Severity Index (PASI) is based on the investigator's assessment of the disease.\nThe extent and severity of redness, thickness and scaliness of psoriasis are recorded for three regions (arms, trunk and legs) and these are used to calculate PASI. The PASI can range between 0 (best) to 64.8 (worst). m-PASI indicate that the scale is modified.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Efficacy: Percentage Change in m-PASI From Baseline to Day 28", 
                                    "units": "percentage of change"
                                }
                            ]
                        }, 
                        "safety_issue": "No", 
                        "time_frame": "Baseline to Day 28", 
                        "title": "Efficacy: Percentage Change in m-PASI From Baseline to Day 28", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Subjects with 'clear' or 'almost clear' disease by investigator's globala ssessment at day 28.\nInvestigator global assessment (IGA) is based on the investigator\u2019s assessment of the disease severity (Plaque thickening, Scaling and Erythema) using a 6-point scale (Clear,Almost clear, Mild,Moderate, Severe, and Very severe). The assessment represents the average lesion severity on the trunk and limbs. IGA can range between 1 (best) and 6 (worst). The assessment is based on the condition of the disease at the time of evaluation, and not in relation to the condition at a previous visit.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                                "title": "LEO 90105 Ointment"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "6"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Subjects with 'clear' or 'almost clear' disease by investigator's globala ssessment at day 28.\nInvestigator global assessment (IGA) is based on the investigator\u2019s assessment of the disease severity (Plaque thickening, Scaling and Erythema) using a 6-point scale (Clear,Almost clear, Mild,Moderate, Severe, and Very severe). The assessment represents the average lesion severity on the trunk and limbs. IGA can range between 1 (best) and 6 (worst). The assessment is based on the condition of the disease at the time of evaluation, and not in relation to the condition at a previous visit.", 
                                    "param": "Number", 
                                    "title": "Efficacy: Subjects With 'Clear' or 'Almost Clear' Disease by Investigator's Global Assessment at Day 28.", 
                                    "units": "participants"
                                }
                            ]
                        }, 
                        "safety_issue": "No", 
                        "time_frame": "Day 28", 
                        "title": "Efficacy: Subjects With 'Clear' or 'Almost Clear' Disease by Investigator's Global Assessment at Day 28.", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                        "title": "LEO 90105 Ointment"
                    }
                }, 
                "period_list": {
                    "period": {
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "13", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "13", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "0", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }, 
                "pre_assignment_details": "Prior to treatment at Visit 1, a washout period was  completed if the subject was treated or had recently been treated with anti-psoriatic treatments or other relevant medication, as defined by the exclusion criteria. The washout period could last up to a maximum of 4 weeks.", 
                "recruitment_details": "First subject first visit: 09-Jul-2012 Last subject last visit: 30-Oct-2012"
            }, 
            "point_of_contact": {
                "email": "ctr.disclosure@leo-pharma.com", 
                "name_or_title": "Clinical trial disclosure manager", 
                "organization": "LEO Pharma A/S", 
                "phone": "00 45 44 94 58 88"
            }, 
            "reported_events": {
                "group_list": {
                    "group": {
                        "@group_id": "E1", 
                        "description": "Subjects received once daily topical treatment with LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate ointment) on all lesions on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) for 4 weeks. Subjects were supplied with an amount of medication at day 1, day 7 and day 14 such that the maximum usage of LEO 90105 could be 90 g per week.", 
                        "title": "LEO 90105 Ointment"
                    }
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "4", 
                                            "@subjects_at_risk": "13"
                                        }, 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "13"
                                        }, 
                                        "sub_title": "Abdominal discomfort"
                                    }
                                }, 
                                "title": "Gastrointestinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "13"
                                        }, 
                                        "sub_title": "Folliculitis"
                                    }
                                }, 
                                "title": "Infections and infestations"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "13"
                                        }, 
                                        "sub_title": "Skin injury"
                                    }
                                }, 
                                "title": "Injury, poisoning and procedural complications"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "13"
                                        }, 
                                        "sub_title": "Arthralgia"
                                    }
                                }, 
                                "title": "Musculoskeletal and connective tissue disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "13"
                                        }, 
                                        "sub_title": "Orthostatic hypotension"
                                    }
                                }, 
                                "title": "Vascular disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment", 
                    "default_vocab": "MedDRA 14.0", 
                    "frequency_threshold": "5"
                }
            }
        }, 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Psoriasis Vulgaris", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Japanese subjects having understood and signed a written informed consent form prior\n             to any study related procedures being carried out (including activities related to\n             the wash out period)\n\n          -  20 years of age or above.\n\n          -  Either sex.\n\n          -  Clinical diagnosis of psoriasis vulgaris amenable to topical treatment involving arms\n             and/or trunk and/or legs.\n\n          -  Psoriasis vulgaris on the trunk/limbs (excluding psoriasis on the genitals/skin\n             folds) of not more than 30% body surface area (BSA)\n\n          -  An Investigator's global assessment of disease severity (IGA) on area(s) to be\n             treated of moderate, severe or very severe and a m-PASI score of \u226512.\n\n          -  Females of childbearing potential must have a negative result for a urine pregnancy\n             test at Day 1 (Visit 1) and must agree to use an adequate method of birth control, as\n             judged by the (sub)investigator, during the study. The contraceptive method should\n             have started an adequate amount of time before the pregnancy test, which is dependent\n             on the particular method used and as judged by the (sub)investigator, and must\n             continue for at least 1 week after the last application of study medication. A female\n             is defined as not of child-bearing potential if she is postmenopausal (12 months with\n             no menses without an alter-native  medical cause) or surgically sterile (tubal\n             ligation /section, hysterectomy or bilateral ovariectomy).\n\n        Exclusion Criteria:\n\n          -  Systemic use of biological treatments with a potential effect on psoriasis vulgaris\n             within the following time periods prior to  Visit 1:\n\n          -  etanercept, adalimumab, infliximab -3 months.\n\n          -  ustekinumab - 4 months\n\n          -  other products - within 3 months/5 half-lives (whichever is longer).\n\n          -  Systemic treatments with all therapies other than biological treatments with a\n             potential effect on psoriasis vulgaris (e.g., corticosteroids, vitamin D analogues,\n             retinoids, immu-nosuppressants such as ciclosporin and methotrexate) within 4 weeks\n             prior to Visit 1 (use of inhaled and nasal corticosteroids is allowed, use of\n             systemic antihistamines is allowed).\n\n          -  Topical treatment of scalp psoriasis with vitamin D analogues (e.g. calcipotriol,\n             tacalcitol, maxacalcitol), or very potent WHO group IV corticosteroids within 2 weeks\n             prior to Visit 1.\n\n          -  PUVA therapy, UVB therapy or UVA therapy within 4 weeks prior to Visit 1.\n\n          -  Topical treatment of psoriasis on the face, genitals or skin folds with vitamin D\n             analogues (e.g. calcipotriol, tacalcitol, maxacalcitol), or potent or very potent WHO\n             group III or IV corticosteroids within 2 weeks prior to Visit 1.\n\n          -  Topical treatment of psoriasis on area(s) to be treated with study medication within\n             the 2-week period prior to Visit 1. (Use of emollients is allowed during this 2- week\n             period, but not during the study.)\n\n          -  Planned initiation of, or changes in, concomitant medication that may affect\n             psoriasis vulgaris (e.g., beta-blockers, antimalaria drugs, lithium and ACE\n             inhibitors) during the study.\n\n          -  Topical treatment of conditions other than psoriasis with vitamin D analogues (e.g.\n             calcipotriol, tacalcitol, maxacalcitol), or potent or very potent WHO group III or IV\n             corti-costeroids within 2 weeks prior to Visit 1.\n\n          -  Current diagnosis of erythrodermic, exfoliative, guttate or pustular psoriasis.\n\n          -  Clinical signs or symptoms of Cushing's disease or Addison's disease\n\n          -  Patients with any of the following disorders (a) or symptoms (b) present on the\n             area(s) to be treated with study medication: (a) viral (e.g., herpes or varicella)\n             lesions of the skin, fungal or bacterial skin infections, parasitic infections, skin\n             manifestations in relation to syphilis or tuberculosis, rosacea, acne vulgaris,\n             atrophic skin, striae atrophicae, ichthyosis, acne rosacea, ulcers, burns, frostbite,\n             wounds, or (b) fragility of skin veins.\n\n          -  Other inflammatory skin diseases (e.g., seborrhoeic dermatitis, contact dermatitis\n             and cutaneous mycosis) that may confound the evaluation of psoriasis vulgaris.\n\n          -  Planned excessive exposure of treated areas(s) to either natural or artificial\n             sunlight (including tanning boths, sun lamps, etc) during the study.\n\n          -  Known or suspected disorders of calcium metabolism associated with hypercalcaemia\n             (subjects with results for albumin-corrected serum calcium above the reference range\n             from the sample taken at the Washout/Screening Visit.\n\n          -  Severe renal insufficiency, severe hepatic disorders or severe heart disease.\n\n          -  Known or suspected hypersensitivity to components of the investigational products.\n\n          -  Current participation in any other interventional clinical study\n\n          -  Subjects who have received treatment with any non-marketed drug substance (i.e. an\n             agent which has not yet been made available for clinical use following registration)\n             within the 4-week period prior to Visit 1 or longer, if the class of substance\n             re-quires a longer washout as defined above (e.g. biological treatments).\n\n          -  Females who are pregnant, wishing to become pregnant during the study, or are\n             breast-feeding\n\n          -  Patients suspected of being unable to comply with the study protocol, e.g. due to\n             alcoholism, drug dependence or psychotic state.\n\n          -  Previous enrollment in this study.\n\n          -  Hospitalised patients."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 10, 2013", 
        "firstreceived_results_date": "November 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01768013", 
            "org_study_id": "MCB 0904"
        }, 
        "intervention": {
            "arm_group_label": "LEO 90105 Ointment", 
            "description": "Once daily for four weeks", 
            "intervention_name": "LEO 90105", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Betamethasone-17,21-dipropionate", 
                "Betamethasone", 
                "Betamethasone sodium phosphate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The mean Cmax(Maximum Observed Plasma Concentration) of betamethasone dipropionate was determined.", 
                "measure": "Pharmacokinetic: Cmax of Betamethasone Dipropionate", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone dipropionate was determined", 
                "measure": "Pharmacokinetic: Cmax of Betamethasone Dipropionate", 
                "safety_issue": "Yes", 
                "time_frame": "Day 7"
            }, 
            {
                "description": "The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone dipropionate was determined", 
                "measure": "Pharmacokinetic: Cmax of Betamethasone Dipropionate", 
                "safety_issue": "Yes", 
                "time_frame": "Day 14"
            }, 
            {
                "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone dipropionate was determined", 
                "measure": "Pharmacokinetic: AUClast of Betamethasone Dipropionate", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone dipropionate was determined", 
                "measure": "Pharmacokinetic: AUClast of Betamethasone Dipropionate", 
                "safety_issue": "Yes", 
                "time_frame": "Day 7"
            }, 
            {
                "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone dipropionate was determined", 
                "measure": "Pharmacokinetic: AUClast of Betamethasone Dipropionate", 
                "safety_issue": "Yes", 
                "time_frame": "Day 14"
            }, 
            {
                "description": "The mean Cmax(Maximum Observed Plasma Concentration) of betamethasone 17- propionate was determined", 
                "measure": "Pharmacokinetic: Cmax of Betamethasone 17-propionate", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone 17- propionate was determined", 
                "measure": "Pharmacokinetic: Cmax of Betamethasone 17-propionate", 
                "safety_issue": "Yes", 
                "time_frame": "Day 7"
            }, 
            {
                "description": "The mean Cmax (Maximum Observed Plasma Concentration) of betamethasone 17- propionate was determined", 
                "measure": "Pharmacokinetic: Cmax of Betamethasone 17-propionate", 
                "safety_issue": "Yes", 
                "time_frame": "Day 14"
            }, 
            {
                "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone 17-propionate was determined", 
                "measure": "Pharmacokinetic: AUClast of Betamethasone 17-propionate", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone 17-propionate was determined", 
                "measure": "Pharmacokinetic: AUClast of Betamethasone 17-propionate", 
                "safety_issue": "Yes", 
                "time_frame": "Day 7"
            }, 
            {
                "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for betamethasone 17-propionate was determined", 
                "measure": "Pharmacokinetic: AUClast of Betamethasone 17-propionate", 
                "safety_issue": "Yes", 
                "time_frame": "Day 14"
            }, 
            {
                "description": "The mean Cmax (Maximum Observed Plasma Concentration) of calcipotriol was determined", 
                "measure": "Pharmacokinetic: Cmax of Calcipotriol", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "The mean Cmax (Maximum Observed Plasma Concentration) of calcipotriol was determined", 
                "measure": "Pharmacokinetic: Cmax of Calcipotriol", 
                "safety_issue": "Yes", 
                "time_frame": "Day 7"
            }, 
            {
                "description": "The mean Cmax (Maximum Observed Plasma Concentration) of calcipotriol was determined", 
                "measure": "Pharmacokinetic: Cmax of Calcipotriol", 
                "safety_issue": "Yes", 
                "time_frame": "Day 14"
            }, 
            {
                "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for calcipotriol was determined", 
                "measure": "Pharmacokinetic: AUClast of Calcipotriol", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for calcipotriol was determined", 
                "measure": "Pharmacokinetic: AUClast of Calcipotriol", 
                "safety_issue": "Yes", 
                "time_frame": "Day 7"
            }, 
            {
                "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for calcipotriol was determined", 
                "measure": "Pharmacokinetic: AUClast of Calcipotriol", 
                "safety_issue": "Yes", 
                "time_frame": "Day 14"
            }, 
            {
                "description": "The mean Cmax (Maximum Observed Plasma Concentration) of MC1080 was determined", 
                "measure": "Pharmacokinetic: Cmax of MC1080", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "The mean Cmax (Maximum Observed Plasma Concentration) of MC1080 was determined", 
                "measure": "Pharmacokinetic: Cmax of MC1080", 
                "safety_issue": "Yes", 
                "time_frame": "Day 7"
            }, 
            {
                "description": "The mean Cmax (Maximum Observed Plasma Concentration) of MC1080 was determined", 
                "measure": "Pharmacokinetic: Cmax of MC1080", 
                "safety_issue": "Yes", 
                "time_frame": "Day 14"
            }, 
            {
                "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for MC 1080 was determined", 
                "measure": "Pharmacokinetic: AUClast of MC1080", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "To assess the The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for MC 1080 was determined", 
                "measure": "Pharmacokinetic: AUClast of MC1080.", 
                "safety_issue": "Yes", 
                "time_frame": "Day 7"
            }, 
            {
                "description": "The mean AUClast (Area under the Plasma Concentration-Time Curve from Time 0 to the Last Observed Measurable Concentration) for MC 1080 was determined", 
                "measure": "Pharmacokinetic: AUClast of MC1080.", 
                "safety_issue": "Yes", 
                "time_frame": "Day 14"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01768013"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Psoriasis Area and Severity Index (PASI) is based on the investigator's assessment of the disease.\nThe extent and severity of redness, thickness and scaliness of psoriasis are recorded for three regions (arms, trunk and legs) and these are used to calculate PASI. The PASI can range between 0 (best) to 64.8 (worst). m-PASI indicate that the scale is modified.", 
                "measure": "Efficacy: Percentage Change in m-PASI From Baseline to Day 28", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Day 28"
            }, 
            {
                "description": "Subjects with 'clear' or 'almost clear' disease by investigator's globala ssessment at day 28.\nInvestigator global assessment (IGA) is based on the investigator's assessment of the disease severity (Plaque thickening, Scaling and Erythema) using a 6-point scale (Clear,Almost clear, Mild,Moderate, Severe, and Very severe). The assessment represents the average lesion severity on the trunk and limbs. IGA can range between 1 (best) and 6 (worst). The assessment is based on the condition of the disease at the time of evaluation, and not in relation to the condition at a previous visit.", 
                "measure": "Efficacy: Subjects With 'Clear' or 'Almost Clear' Disease by Investigator's Global Assessment at Day 28.", 
                "safety_issue": "No", 
                "time_frame": "Day 28"
            }
        ], 
        "source": "LEO Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LEO Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}